anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to an Odorrana grahami immunomodulation peptide, gene and variant and the application in the pharmacy belonging to the biomedicine field. The Odorrana grahami immunomodulation peptide is a circular peptide with a molecular weight of 1791.12 D and a isoelectric point of 9.84. The whole sequence of the Odorrana grahami immunomodulation peptide is Thr Ser Arg Cys Tyr Ile Gly Tyr Arg Arg Lys Val Val Cys Ser (TSRCYIGYRRKVVCS), wherein the fourth cysteine and 14th cysteine form intramolecular disulfide bond. The code gene is composed of 307 nucleotides, wherein the code mature parts are from 141th to 186th nucleotide. The produced variant is produced by substituting the fourth amino acid in the original sequence of the Odorrana grahami immunomodulation peptide. The artificial synthetic Odorrana grahami immunomodulation peptide and variant thereof has a strong immunomodulation activity and tumor resistance activity and can be used for immunomodulation, tumor treatment and chemotherapeutics. The invention has the advantages such as simple sequence and convenient synthesis.
Phospholipids from the group B streptococcal (GBS) cell wall cause pulmonary hypertension in experimental animals. We hypothesize that newborns colonized with GBS receive bacterial phospholipids leading to pulmonary hypertension and respiratory distress. When exposed to penicillin (beta-lactam), Streptococcus mutans releases phospholipids immediately. An analysis of 1610 colonized newborns from the NICHD GBS study conducted in six academic centers from 1995 to 1999 showed that 8.8% of GBS colonized newborns greater than or equal to 32 weeks gestation had signs of respiratory distress as compared to 1-3% observed in general newborn populations, and that beta-lactam use during labor was associated with 2.62 fold increase in respiratory distress in the colonized newborns. These findings support the association of neonatal respiratory distress with GBS colonization and with penicillin use during labor. These data however require confirmation.

We now plan to conduct a prospective study to relate the levels of serum bacterial phospholipids to the occurrence of respiratory distress in newborns of mother colonized GBS. This study will also evaluate the effect of beta-lactam use during labor on the release of phospholipids and therefore the occurrence of respiratory distress in newborns of mothers colonized with GBS. The study will be conducted at the Baylor College of Medicine and Oakland Children s Hospital and Research Center. Serum phospholipid levels will be measured in newborns with respiratory distress, newborns of mothers colonized by GBS, treated or untreated with beta-lactam during labor.
Chronic pain (CP) and mental illness (MI) are leading causes of years lived with disability and commonly co-occur. However, it remains unclear if available interventions are effective in improving pain outcomes in patients with co-existing CP and MI. This systematic review synthesised evidence for the effectiveness of interventions to improve pain outcomes for people with comorbid CP and clinically diagnosed MI. Ten electronic databases were searched from inception until May 2023. Randomised controlled trials (RCTs) were included if they evaluated interventions for CP-related outcomes among people with comorbid CP and clinically diagnosed MI. Pain-related and mental health outcomes were reported as primary and secondary outcomes, respectively. 26 RCTs (2,311 participants) were included. Four trials evaluated the effectiveness of cognitive-behavioural therapy, 6 mindfulness-based interventions, 1 interpersonal psychotherapy, 5 body-based interventions, 5 multi-component interventions, and 5 examined pharmacological-based interventions. Overall, there was considerable heterogeneity in sample characteristics and interventions, and included studies were generally of poor quality with insufficient trial details being reported. Despite the inconsistency in results, preliminary evidence suggests interventions demonstrating a positive effect on CP may include cognitive-behavioural therapy for patients with depression (with a small to medium effect size) and multi-component intervention for people with substance use disorders (with a small effect size). Despite the high occurrence/burden of CP and MI, there is a relative paucity of RCTs investigating interventions and none in people with severe MI. More rigorously designed RCTs are needed to further support our findings. PERSPECTIVE: This systematic review presents current evidence evaluating interventions for CP-related and MH outcomes for people with comorbid CP and clinically diagnosed MI. Our findings could potentially help clinicians identify the most effective treatments to manage these symptoms for this vulnerable patient group.
The invention belongs to the field of pharmacy, and relates to a novel application of a flavan compound in preparing anti-complement medicines. According to the invention, a modern pharmacological screening method is applied, and researches are carried out upon anti-complement active substances in plant medicines. According to the invention, the flavan compound is obtained by separation from an n-butanol extract of a commelinaceae plant commelina and an n-butanol extract of a polygonum plant fagopyrum. With an in-vitro complement activity evaluation test, it is verified that the compound has high inhibition effect upon classical pathway and alternative pathway of a complement system. The CH50 of the inhibition effect of the compound upon the classical pathway of the complement system is 0.13 (plus or minus 0.03)-0.78 (plus or minus 0.06) mM, and the AP50 of the inhibition effect of the compound upon the alternative pathway of the complement system is 0.12 (plus or minus 0.01)-1.00 (plus or minus 0.15) mM. The compound can be used for preparing anti-complement medicines.
PROBLEM TO BE SOLVED: To obtain the subject new compound useful as a perfume substance, having enhanced herbal-like and green-like fragrance and flavor characteristics and excellent durability of the characteristics. SOLUTION: This compound is 1-(6,6-dimethyl-2-methylenecyclohexan-1-yl) propan-2-one of formula I. 3,3-Dimethyl-1-cyclohexenylmethanol of formula II is catalytically reacted with isopropenyl methyl ether of formula III in the presence of an acid catalyst (e.g. pivalic acid) at 100-300 deg.C C for 0.5-5 hours to give the objective compound. The compound of formula III in an amount of 5-50mol is used based on 1mol of the compound of formula 1 and 0.01-0.1mol of the acid catalyst. Preferably the reaction is carried out in an inert gas atmosphere in a closed container. A perfume composition contains 0.001-30wt.% based on the total of the composition of the compound of formula I to give a fragrance and flavor imparting composition.
Begin DOPTELET dosing 10 to 13 days prior to the scheduled procedure. The recommended daily dose of DOPTELET is based on the patient’s platelet count prior to the scheduled procedure (see Table 1). Patients should undergo their procedure 5 to 8 days after the last dose of DOPTELET.

DOPTELET should be taken orally once daily for 5 consecutive days with food. In the case of a missed dose, patients should take the next dose of DOPTELET as soon as they remember. Patients should not take two doses at one time to make up for a missed dose, and should take the next dose at the usual time the next day; all 5 days of dosing should be completed.

Table 1: Recommended Dose and Duration in Patients with Chronic Liver Disease Scheduled to Undergo a Procedure

DOPTELET has been investigated only as a single 5-day once daily dosing regimen in clinical trials in patients with chronic liver disease [see Clinical Studies (14.1)]. DOPTELET should not be administered to patients with chronic liver disease in an attempt to normalize platelet counts.

Monitoring: Obtain a platelet count prior to administration of DOPTELET therapy and on the day of a procedure to ensure an adequate increase in platelet count.
Systems, methods, and instrumentalities are disclosed herein for allowing a patient to check in for a visit to a provider while creating a record of the patient being physically present at the provider's office at the time of the visit. The patient may scan a QR code associated with the provider using a mobile device. The patient's mobile device may download a questionnaire that may include one or more facility-specific questions, and may prompt the patient to enter biographical information and information. The mobile device may transmit the patient's responses and a unique ID associated with the mobile device, to a cloud server. The cloud server may transmit the responses and the unique ID to a local server in the provider's office. The local server may add the responses and/or the unique ID to a patient record associated with the patient and/or may log the information in an audit log.
Methods of Treating Antipsychotic-Induced Weight Gain with Miricorilant Methods and compositions for treating a subject at risk of, or suffering from antipsychotic-induced weight gain are disclosed. The methods include administration of a cyclohexyl pyrimidine glucocorticoid receptor modulator (GRM) such as miricorilant (CORT118335) to a patient receiving, or who has received, or who is expected to receive, an antipsychotic drug such as olanzapine, risperidone, clozapine, or other weight-inducing antipsychotic medication. The GRM (e.g., miricorilant) may be orally administered. Administration of such a GRM along with antipsychotic medication may reduce the amount of weight, or reduce the rate of weight gain, or prevent weight gain, otherwise due to antipsychotic medication alone. The methods may reverse weight gain in a patient previously administered antipsychotic medication. Administration of such a GRM with antipsychotic medication may reduce, or reduce gain in, or prevent gain in, or reverse gain in, insulin resistance or blood levels of liver enzymes (AST, ALT), triglycerides, or insulin.
BACKGROUND: To investigate the association between maternal sepsis during pregnancy and poor pregnancy outcome and to identify risk factors for poor birth outcomes and adverse perinatal events.
METHODS: We linked the Taiwan Birth Cohort Study (TBCS) database and the Taiwanese National Health Insurance Database (NHID) to conduct this population-based study. We analysed the data of pregnant women who met the criteria for sepsis-3 during pregnancy between 2005 and 2017 as the maternal sepsis cases and selected pregnant women without infection as the non-sepsis comparison cohort. Sepsis during pregnancy and fulfilled the sepsis-3 definition proposed in 2016. The primary outcome included low birth weight (LBW, < 2500 g) and preterm birth (< 34 weeks), and the secondary outcome was the occurrence of adverse perinatal events.
RESULTS: We enrolled 2,732 women who met the criteria for sepsis-3 during pregnancy and 196,333 non-sepsis controls. We found that the development of maternal sepsis was highly associated with unfavourable pregnancy outcomes, including LBW (adjOR 9.51, 95% CI 8.73-10.36), preterm birth < 34 weeks (adjOR 11.69, 95%CI 10.64-12.84), and the adverse perinatal events (adjOR 3.09, 95% CI 2.83-3.36). We also identified that socio-economically disadvantaged status was slightly associated with an increased risk for low birth weight and preterm birth.
CONCLUSION: We found that the development of maternal sepsis was highly associated with LBW, preterm birth and adverse perinatal events. Our findings highlight the prolonged impact of maternal sepsis on pregnancy outcomes and indicate the need for vigilance among pregnant women with sepsis.
The present invention relates to a Chinese medicinal preparation for treating coronary artery disease, cerebral thrombosis and cerebral infarction and a preparation method thereof, which belongs to the technical field of Chinese medicinal preparations and preparation methods thereof. The present invention overcomes the defects of the existing Chinese medicinal preparations for treating the coronary artery disease, the cerebral thrombosis and the cerebral infarction, and increases curative effects. The preparation is composed of the raw medicinal materials of the following part by weight: 1.5 to 4 parts of prepared leech, 2 to 3.5 parts of prepared fankincense, 2 to 3.5 parts of prepared myrrh, 1 to 3.5 parts of Chinese ephedra, 3 to 6 parts of prepared earthworm, 5 to 8.5 parts of hemlock parsley, and 2 to 3.5 parts of almond. The compatibility of the medicinal materials has significant curative effects on symptoms, such as low cardiac cerebral blood flow, low myocardial oxygen delivery, etc., of the coronary artery disease, the cerebral thrombosis and the cerebral infarction. The systematic observation of relative indexes, such as blood fat, blood flow change, etc., and the influence on cardiac cerebral functions in clinic shows that the preparation has good curative effects. The present invention has simple preparation method and low cost.
Participants in this arm will test how effective hypofractionated/shortened whole radiation treatment is ("efficacy") at the dose established in the first phase of this study by following up with their doctors to report their current health status and symptoms during clinical visits. Participants will return for routine clinical follow-up approximately 1 month following radiation, then at 3 months following radiation, then every 3 months for the next 2 years following treatment.
Abrocitinib will be self-administered as 200-milligram (mg) tablet daily for 52 weeks (12 months). The final prepared product is to be labeled to protect the blind.
Multi-modal exercise programme The 10-week multi-modal exercise programme will comprise of twice weekly online supervised group-based exercise sessions. Each exercise session will last approximately 1 hour and consist of a combination of aerobic, resistance and balance and flexibility exercises.
Both groups (EG and CG) received BTI training in a short 2.5-hour format in groups of 13-16 students. The content included: 1) general information and epidemiology of smoking, 2) passive smoking, 3) evidence of the effectiveness of tobacco interventions, and 4) the approach to smoking cessation in Primary Care as proposed by the WHO using the 5 As and 5 Rs model to help patients quit smoking (World Health Organization, 2014). This model outlines the five main steps of the 5 As (Ask, Advise, Assess, Assist, and Arrange) for providing brief intervention in primary care settings and the 5 Rs (Relevance, Risks, Rewards, Roadblocks, and Repetition) to address with smokers who are not yet ready to quit.
The invention discloses a hair care liquid and relates to hair care liquid improvement. The hair care liquid is conducive to hair growth and can effectively protect brain physical health. The hair care liquid is mainly prepared from 0.5-1.25wt% of wheat germ, 0.9-1.65wt% of mushroom, 0.6-1.15wt% of Chinese angelica, 20-25wt% of condensed milk, 0.8-1.85wt% of pinellia ternate, 1.5-3.5wt% of Chinese herbaceous peony, 15-20wt% of ginger and 45-65wt% of wine. The hair care liquid promotes absorption of nutrients outside scalp, promotes blood circulation and improves a hair nutrition state. The hair care liquid contains trace elements such as a plurality of amino acids, zinc and iodine, and mineral matters. Through natural absorption by hair, scalp and hair follicles, hair and brain nutritional requirement are satisfied. Through use of the traditional Chinese medicine components, the hair care liquid has effects of promoting blood circulation to remove blood stasis, activating skin, repairing hair follicles and protecting brain physical health.
Supracondylar femur fractures in the geriatric population present a unique challenge to the orthopaedic surgeon both in terms of fixation, healing, and final extremity axial alignment. Multiple methods of fixation are well accepted, and each has its own advantages and disadvantages. The common occurrence of periprosthetic supracondylar femur fractures adds another level of complexity, and the universal goal when treating these patients is to obtain and maintain acceptable alignment, allow mobilization and early weight bearing, and achieve union. To a degree, mobilization and weight bearing compete with maintenance of axial alignment, and any final outcome is a race between healing and loss of fixation. As a result, any intervention that can accelerate healing would be of great benefit. As the vast majority of these injuries heal with secondary bone healing (callous), the determination of "healing" is reliably determined using the modified Radiographic Union Score for Tibia Fractures (mRUST), and thus this patient population offers an ideal population in which to evaluate an accelerant of fracture healing.

Pulsed dosing of parathyroid hormone derivatives (Forteo) has been shown to increase bone mass, and several studies in Europe have demonstrated its benefit as an adjuvant for fracture healing. Abaloparatide represents a new compound which similarly offers great potential for accelerating fracture healing, especially healing associated with callous formation. This is a randomized, double blind placebo-controlled trial to compare a group of patients being treated for supracondylar distal femur fractures who receive abaloparatide (n=38) with a control group of patients who receive a placebo (n=38).
In the short-season winter environment of India and Bangladesh, lentil growth and seed yield are significantly hindered by foliar blight caused by Stemphylium botryosum. As the international germplasm pool lacks a resistance source, the study aims to develop a mutant population to identify a high-yielding mutant resistance against the pathogen. A gamma-irradiated population was developed based on its GR50 dose of 248.8 Gy. The screening of almost 130,000 M2 plants identified a tolerant lentil mutant, MM216. The multi-location trials revealed that MM216 showed an impressive and robust resistance; the selected mutant line could be recommended as a donor in the lentil breeding program against the pathogen globally. A 100 g seed was exposed to a GR50 dose to develop the M1 population. At maturity, at least 100 M2 seeds of each 1300 M1 plant were harvested individually. So, almost 130,000 M2 plants were screened in the disease hot spot. The selected mutants were advanced to M7 by screening in the field and challenged in controlled conditions with the pure pathogen isolate. A resistance mutant, MM216, with a per cent disease index (PDI) of <10, was identified where the mean of the check varieties, WBL 77, was >55. The resistance ability was confirmed further in controlled conditions. The fungal and plant DNA ratio was almost negligible in the tolerant mutant, whereas it was 0.17 in WBL77 at 196 h post-inoculation. The selected mutant did not display any yield penalty, but there was a delay in flowering by a week compared to WBL77.
PROBLEM TO BE SOLVED: To obtain the subject medicine capable of readily preparing and forming in small size so that aged persons can readily swallow it by including magnesium aluminometasilicate. SOLUTION: This medicine is obtained by adding magnesium aluminometasilicate whose water absorption amount is 1.8-2.2 mL/g as additive for pharmaceutical preparation to loxoprofen sodium which is well-known as an analgesic, anti-inflammatory and antipyretic agent. The magnesium aluminometasilicate is formulated in an amount of 10-80 wt.% based on loxoprofen (as anhydride). The medicine is tableted, preferably in 7.5-8.2 mm diameter by well-known method such as dry type granulation or wet type granulation. Thereby, the medicine can be prepared in small size capable of readily ingesting without giving restriction in which total water absorption ability is >=1.7 and without trouble in preparation process. Since the medicine is small- sized tablet, production cost of the medicine can be reduced.
The recommended dose of Amoxicillin and Clavulanate Potassium Extended Release Tablets is 4,000 mg/250 mg daily according to the following table:

Tablets of Amoxicillin and Clavulanate Potassium (250 mg or 500 mg) CANNOT be used to provide the same dosages as Amoxicillin and Clavulanate Potassium Extended Release Tablets. This is because Amoxicillin and Clavulanate Potassium Extended Release Tablets contain 62.5 mg of clavulanic acid, while the Amoxicillin and Clavulanate Potassium 250-mg and 500-mg tablets each contain 125 mg of clavulanic acid. In addition, the Extended Release Tablet provides an extended time course of plasma amoxicillin concentrations compared to immediate-release Tablets. Thus, two Amoxicillin and Clavulanate Potassium 500-mg tablets are not equivalent to one Amoxicillin and Clavulanate Potassium Extended Release Tablet.

Scored Amoxicillin and Clavulanate Potassium Extended Release Tablets are available for adult patients who have difficulty swallowing. The scored tablet is not intended to reduce the dosage of medication taken; as stated in the table above, the recommended dose of Amoxicillin and Clavulanate Potassium Extended Release Tablet is two tablets twice a day (every 12 hours).
Subjects belonging to this group perform a 12-week supervised exercise. Treadmill walking exercise. Participants must complete four four-minute blocks at an intensity of 85-95% of peak heart rate.
Patients will receive the computer-assisted preoperative CBT intervention (n=75). A particularly promising internet-based CBT pain program for the population of interest, PAINTrainer, demonstrated improved pain, function, coping and global health in patients with chronic knee arthritic pain in comparison to an internet education control, with benefits persisting for up to 52 weeks. In addition to the PAINTrainer, there will be an integration of a motivational interviewing (MI) intervention delivered by a trained "coach" across the sessions about (1) the benefits of opioid tapering for post-operative pain control, (2) approaches for safely tapering, (3) identifying and managing withdrawal symptoms patients may experience.
The target population consists of patients between 10 and 19 years old, attending the Adolescent Clinic in the Dental School of the Federal University of Pernambuco (UFPE), campus of Recife. The sample will consist of 184 adolescents, 92 in each group (intervention and control). Randomization will be stratified according to sex, age and presence or absence of dental anxiety. In the waiting room, before the dental appointment, the adolescents in the intervention group (IG) will use the FALE application to answer the questionnaire and assess the level of anxiety. Those in the control group (CG) will only record their level of anxiety. The undergraduates responsible for attending the IG participants will receive, prior to dental care, a report of the answers given by the adolescents through the application. During the dental consultation, a psychologist, who will be observing the care, will evaluate the adolescents behavior, considering cooperation. After the appointment, the adolescent will evaluate how much he/she felt benefited by the use of the app; how he evaluates the communication between him/her and the dentist; if he/she thinks that the app contributed with this communication; his/her satisfaction with dental treatment; and his/her satisfaction with the undergraduate attendance. The undergraduate will also evaluate his/her level of satisfaction with the application's use; how he/she evaluates the communication between him/her and the adolescent patient; how much the application has helped with this communication; and the degree of patient's cooperation during the dental consultation. Descriptive and inferential statistical analysis will be performed using appropriate tests through the Statistical Package for Social Sciences software version 21 and significance level of 5%.